Cargando…
MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988629/ http://dx.doi.org/10.1186/s42077-021-00148-4 |
| _version_ | 1783668821705359360 |
|---|---|
| author | Chilkoti, Geetanjali T. Gondode, Prakash G. Tiwari, Spriha S. |
| author_facet | Chilkoti, Geetanjali T. Gondode, Prakash G. Tiwari, Spriha S. |
| author_sort | Chilkoti, Geetanjali T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7988629 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79886292021-03-24 MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? Chilkoti, Geetanjali T. Gondode, Prakash G. Tiwari, Spriha S. Ain-Shams J Anesthesiol Letter to the Editor Springer Berlin Heidelberg 2021-03-24 2021 /pmc/articles/PMC7988629/ http://dx.doi.org/10.1186/s42077-021-00148-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Chilkoti, Geetanjali T. Gondode, Prakash G. Tiwari, Spriha S. MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title | MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title_full | MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title_fullStr | MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title_full_unstemmed | MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title_short | MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better? |
| title_sort | mdi or nebulization in moderate to severe covid-19 disease with copd: which one is better? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988629/ http://dx.doi.org/10.1186/s42077-021-00148-4 |
| work_keys_str_mv | AT chilkotigeetanjalit mdiornebulizationinmoderatetoseverecovid19diseasewithcopdwhichoneisbetter AT gondodeprakashg mdiornebulizationinmoderatetoseverecovid19diseasewithcopdwhichoneisbetter AT tiwarisprihas mdiornebulizationinmoderatetoseverecovid19diseasewithcopdwhichoneisbetter |